Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes

被引:65
作者
Di Filippo, M. [1 ,2 ,3 ]
Anderson, V. M. [2 ,3 ]
Altmann, D. R. [2 ,5 ]
Swanton, J. K. [2 ,3 ]
Plant, G. T. [6 ]
Thompson, A. J. [2 ,4 ]
Miller, D. H. [2 ,3 ]
机构
[1] Univ Perugia, Multiple Sclerosis Ctr, Neurol Sect, I-06100 Perugia, Italy
[2] UCL Inst Neurol, NMR Res Unit, London, England
[3] UCL Inst Neurol, Dept Neuroinflammat, London, England
[4] UCL Inst Neurol, Dept Brain Repair & Rehabil, London, England
[5] London Sch Hyg & Trop Med, Med Stat Unit, London WC1, England
[6] Moorfields Eye Hosp, Neuroophthalmol Clin, London, England
关键词
REMITTING MULTIPLE-SCLEROSIS; GREY-MATTER ATROPHY; PLACEBO-CONTROLLED TRIAL; TERM-FOLLOW-UP; NEUROLOGIC IMPAIRMENT; DIAGNOSTIC-CRITERIA; OPTIC NEURITIS; DOUBLE-BLIND; MRI; DISABILITY;
D O I
10.1136/jnnp.2009.171769
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Conventional MRI lesion measures modestly predict long term disability in some clinically isolated syndrome (CIS) studies. Brain atrophy suggests neuroaxonal loss in multiple sclerosis (MS) with the potential to reflect disease progression to a greater extent than lesion measures. Objective To investigate whether brain atrophy and lesion load, during the first year in patients presenting with CIS, independently predict clinical outcome (development of MS and disability at 6 years). Methods 99 patients presenting with CIS were included in the study. T1 gadolinium enhanced and T2 weighted brain MRI was acquired at baseline and approximately 1 year later. Percentage brain atrophy rate between baseline and follow-up scans was analysed using SIENA. Results Mean annual brain atrophy rates were -0.38% for all patients, -0.50% in patients who had developed MS at 6 years and -0.26% in those who had not. Brain atrophy rate (p=0.005) and baseline T2 lesion load (p<0.001) were independent predictors of clinically definite MS. While brain atrophy rate was a predictor of Expanded Disability Status Scale (EDSS) score in a univariate analysis, only 1 year T2 lesion load change (p=0.007) and baseline gadolinium enhancing lesion number (p=0.03) were independent predictors of EDSS score at the 6 year follow-up. T1 lesion load was the only MRI parameter which predicted Multiple Sclerosis Functional Composite score at the 6 year follow-up. Conclusions The findings confirm that brain atrophy occurs during the earliest phases of MS and suggest that 1 year longitudinal measures of MRI change, if considered together with baseline MRI variables, might help to predict clinical status 6 years after the first demyelinating event in CIS patients, better than measurements such as lesion or brain volumes on baseline MRI alone.
引用
收藏
页码:204 / 208
页数:5
相关论文
共 41 条
[1]   Cerebral atrophy measurement in clinically isolated syndromes and relapsing remitting multiple sclerosis: A comparison of registration-based methods [J].
Anderson, Valerie M. ;
Fernando, Kryshani T. M. ;
Davies, Gerard R. ;
Rashid, Waqar ;
Frost, Chris ;
Fox, Nick C. .
JOURNAL OF NEUROIMAGING, 2007, 17 (01) :61-68
[2]  
Beck RW, 2003, ARCH OPHTHALMOL-CHIC, V121, P944
[3]   A longitudinal study of abnormalities on MRI and disability from multiple sclerosis [J].
Brex, PA ;
Ciccarelli, O ;
O'Riordan, JI ;
Sailer, M ;
Thompson, AJ ;
Miller, DH .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (03) :158-164
[4]   Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis [J].
Chard, DT ;
Griffin, CM ;
Rashid, W ;
Davies, GR ;
Altmann, DR ;
Kapoor, R ;
Barker, GJ ;
Thompson, AJ ;
Miller, DH .
MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (04) :387-391
[5]   MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation" [J].
Charil, Arnaud ;
Yousry, Tarek A. ;
Rovaris, Marco ;
Barkhof, Frederik ;
De Stefano, Nicola ;
Fazekas, Franz ;
Miller, David H. ;
Montalban, Xavier ;
Simon, Jack H. ;
Polman, Chris ;
Filippi, Massimo .
LANCET NEUROLOGY, 2006, 5 (10) :841-852
[6]   Multiple sclerosis [J].
Compston, A ;
Coles, A .
LANCET, 2002, 359 (9313) :1221-1231
[7]   Development of a multiple sclerosis functional composite as a clinical trial outcome measure [J].
Cutter, GR ;
Baier, ML ;
Rudick, RA ;
Cookfair, DL ;
Fischer, JS ;
Petkau, J ;
Syndulko, K ;
Weinshenker, BG ;
Antel, JP ;
Confavreux, C ;
Ellison, GW ;
Lublin, F ;
Miller, AE ;
Rao, SM ;
Reingold, S ;
Thompson, A ;
Willoughby, E .
BRAIN, 1999, 122 :871-882
[8]   Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes [J].
Dalton, CM ;
Chard, DT ;
Davies, GR ;
Miszkiel, KA ;
Altmann, DR ;
Fernando, K ;
Plant, GT ;
Thompson, AJ ;
Miller, DH .
BRAIN, 2004, 127 :1101-1107
[9]   Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis [J].
Dalton, CM ;
Brex, PA ;
Jenkins, R ;
Fox, NC ;
Miszkiel, KA ;
Crum, WR ;
O'Riordan, JI ;
Plant, GT ;
Thompson, AJ ;
Miller, DH .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (02) :141-147
[10]   Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial [J].
Filippi, M ;
Rovaris, M ;
Inglese, M ;
Barkhof, F ;
De Stefano, N ;
Smith, S ;
Comi, G .
LANCET, 2004, 364 (9444) :1489-1496